<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179331</url>
  </required_header>
  <id_info>
    <org_study_id>NT-2-19</org_study_id>
    <nct_id>NCT04179331</nct_id>
  </id_info>
  <brief_title>Neurotensin Infusions in Healthy Individuals -</brief_title>
  <acronym>NIHI</acronym>
  <official_title>Neurotensin Infusions in Healthy Individuals - Effects on Appetite, Food Intake, Hormone Secretions and Cardiovascular Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurotensin (NT) is a gut peptide released postprandially from the small intestine. It is&#xD;
      known to exert a range of enterogastrone effects and in animal models it reduces food intake&#xD;
      when administered by parenteral routes.&#xD;
&#xD;
      In this study, after a 1h baseline period, three doses (2.5, 5.0 and 7.5pmol/kg/min) of NT&#xD;
      will be administered in sequence each infusion lasting 1h. On a placebo day saline will be&#xD;
      infused similarly 1h infusions. During the final infusion (7.5pmol/kg/min) an ad libitum meal&#xD;
      will be ingested. During the experiments blood samples will be collected and subjective&#xD;
      perceptions recorded using validated visual analogue scales.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">January 23, 2020</completion_date>
  <primary_completion_date type="Actual">January 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Acute physiological experiments conducted in healthy individuals in a University Hospital setting.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blinded. Neither the investigators performing the experiments or the participants know the nature of the intervention on the two study days.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Food intake</measure>
    <time_frame>From time point t=190-220 minutes</time_frame>
    <description>The amount of food ingested over 30 minutes will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hunger</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiation</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fullness</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective food intake</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirst</measure>
    <time_frame>-45, -15, 15, 45, 75, 105, 135, 165, 220, 250 minutes</time_frame>
    <description>Visual analogue scale (100mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotensin</measure>
    <time_frame>-60, -30, -15, 0, 15, 30, 60, 75, 90, 120, 135, 150, 180, 220 minutes</time_frame>
    <description>plasma concentration (intact and total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic polypeptide</measure>
    <time_frame>-60, -30, -15, 0, 15, 30, 60, 75, 90, 120, 135, 150, 180, 220 minutes</time_frame>
    <description>Plasma concentration (intact and total)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>-60, -30, -15, 0, 15, 30, 60, 75, 90, 120, 135, 150, 180, 220 minutes</time_frame>
    <description>Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin and C-peptide</measure>
    <time_frame>-60, -30, -15, 0, 15, 30, 60, 75, 90, 120, 135, 150, 180, 220 minutes</time_frame>
    <description>Serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>-60 to 250 minutes</time_frame>
    <description>Pulse rate every 10 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>-60 to 250 minutes</time_frame>
    <description>Systolic and diastolic blood pressures (mmHg) every 10 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Neurotensin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurotensin</intervention_name>
    <description>Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.</description>
    <arm_group_label>Neurotensin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Isotonic saline will serve as a placebo.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age = or above 18 years&#xD;
&#xD;
          -  normal haemoglobin levels&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus (fasting plasma glucose or HbA1c)&#xD;
&#xD;
          -  Familiy history of diabetes mellitus&#xD;
&#xD;
          -  Intestinal disease (incl e.g. inflammatory bowel disease and malabsorbtion)&#xD;
&#xD;
          -  Family history of inflammatory bowel disease&#xD;
&#xD;
          -  Previous intestinal resection&#xD;
&#xD;
          -  Body mass index (BMI) over 25 kg/m2&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Nephropathy (S-creatinine&gt; 130 μM)&#xD;
&#xD;
          -  Liver disease (ALAT and/or ASAT &gt; 2 × upper normal limit)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Capital</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Simon Veedfald</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>Appetite regulation</keyword>
  <keyword>Food intake</keyword>
  <keyword>Ad libitum</keyword>
  <keyword>Hormone secretion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

